Guardian Pharmacy Services, Inc. (NYSE:GRDN) Stock Has Average Target Price of $45.57

Shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN) have received an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $45.57.

GRDN has been the topic of a number of recent research reports. Wall Street Zen upgraded Guardian Pharmacy Services from a “hold” rating to a “buy” rating in a research report on Saturday, October 17th. Weiss Ratings raised shares of Guardian Pharmacy Services from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. Oppenheimer raised their target price on Guardian Pharmacy Services from $43.00 to $49.00 and gave the company an “outperform” rating in a research report on Friday, August 7th. KeyCorp began coverage on Guardian Pharmacy Services in a report on Tuesday, September 22nd. They issued an “overweight” rating and a $52.00 price objective on the stock. Finally, Truist Financial increased their target price on Guardian Pharmacy Services from $47.00 to $51.00 and gave the company a “buy” rating in a research report on Monday, September 21st.

Hedge Funds Weigh In On Guardian Pharmacy Services

Hedge funds and other institutional investors have recently made changes to their positions in the company. First Trust Advisors LP acquired a new stake in Guardian Pharmacy Services in the 1st quarter valued at about $3,528,000. Dimensional Fund Advisors LP boosted its holdings in shares of Guardian Pharmacy Services by 200.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 208,594 shares of the company’s stock worth $7,855,000 after purchasing an additional 139,070 shares during the last quarter. Globeflex Capital L P acquired a new position in shares of Guardian Pharmacy Services during the 2nd quarter worth approximately $1,857,000. Bank of America Corp DE grew its position in shares of Guardian Pharmacy Services by 86.1% in the first quarter. Bank of America Corp DE now owns 128,048 shares of the company’s stock valued at $4,822,000 after purchasing an additional 59,245 shares in the last quarter. Finally, Sanctuary Advisors LLC purchased a new stake in shares of Guardian Pharmacy Services in the first quarter valued at approximately $1,352,000.

Guardian Pharmacy Services Trading Up 1.9%

Shares of NYSE:GRDN opened at $39.72 on Friday. The firm’s 50-day moving average is $40.90 and its 200 day moving average is $39.96. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of 38.56, a PEG ratio of 2.04 and a beta of 0.03. Guardian Pharmacy Services has a 12 month low of $26.34 and a 12 month high of $48.33.

Guardian Pharmacy Services (NYSE:GRDN) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.03. Guardian Pharmacy Services had a net margin of 4.50% and a return on equity of 29.97%. The firm had revenue of $351.77 million for the quarter, compared to analysts’ expectations of $340.45 million. As a group, equities analysts forecast that Guardian Pharmacy Services will post 1.18 EPS for the current fiscal year.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc is a provider of pharmacy services focused primarily on residents of long-term care and other institutional healthcare settings. Through its network of pharmacies, the company supplies prescription medications and related pharmacy support to assisted living communities, skilled nursing facilities, behavioral health organizations, and other care providers.

The company’s services include medication dispensing and packaging, prescription delivery, medication management, clinical pharmacy support, and technology-enabled tools designed to help caregivers and healthcare professionals manage residents’ medication regimens.